Simulation of Lipid-Lowering Therapy Intensification for ASCVD

This simulation model study estimates the percentage of patients with atherosclerotic cardiovascular disease who would require proprotein convertase subtilisin/kexin type 9 inhibitor therapy when oral therapy to lower lipid levels is intensified first.

Read the full article here

Related Articles